EGFR and non-small cell lung carcinoma: For patients with resectable stage II and III NSCLC, treatment options have massively increased, with the approval of several immunotherapeutic agents plus PBC in the neoadjuvant or peri-operative setting, as well as the approval of adjuvant tyrosine kinase inhibitors (TKIs) for patients with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) positive NSCLC.